GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Cash Receipts from Fees and Commissions

Soligenix (STU:DOA) Cash Receipts from Fees and Commissions


View and export this data going back to 2007. Start your Free Trial

What is Soligenix Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Soligenix (STU:DOA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).